[Autologous transplant with BEAM protocol in lymphoma].
Caballero
D
D
Servicio de Hematología, Hospital Universitario de Salamanca.
Rubio
V
V
Rifon
J
J
Heras
I
I
García-Sanz
R
R
Vidriales
B
B
Pérez-Simón
J A
JA
del Cañizo
C
C
González
M
M
León
A
A
Jean-Paul
E
E
Rocha
E
E
Vicente
V
V
San Miguel
J F
JF
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous
D003561:Cytarabine; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine